Compare WPC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPC | NBIX |
|---|---|---|
| Founded | 1973 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 15.5B |
| IPO Year | 1998 | 1996 |
| Metric | WPC | NBIX |
|---|---|---|
| Price | $66.31 | $144.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 22 |
| Target Price | $73.11 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.1M | 927.8K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.33 | ★ 3.30 |
| Revenue | ★ $1,716,485,000.00 | $161,626,000.00 |
| Revenue This Year | $6.59 | $24.73 |
| Revenue Next Year | $6.16 | $13.14 |
| P/E Ratio | $49.91 | ★ $44.30 |
| Revenue Growth | 8.43 | ★ 977.51 |
| 52 Week Low | $63.08 | $122.14 |
| 52 Week High | $77.22 | $186.12 |
| Indicator | WPC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 21.56 | 30.58 |
| Support Level | $63.47 | $141.00 |
| Resistance Level | $74.90 | $161.41 |
| Average True Range (ATR) | 1.10 | 4.33 |
| MACD | -0.35 | -0.74 |
| Stochastic Oscillator | 2.30 | 1.21 |
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. majority of the company's revenue comes from properties in the USA. Its Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.